Predictors of response to tofacitinib or etanercept in a Phase 3 randomised, non-inferiority study in patients with moderate to severe chronic plaque psoriasis

被引：0

作者：

Lambert, J. ^{[1
]}

Strohal, R. ^{[2
]}

de la Cruz, C. ^{[3
]}

Thaci, D. ^{[4
]}

Bachelez, H. ^{[5
]}

Iversen, L. ^{[6
]}

Rottinghaus, S. ^{[7
]}

Tallman, A. ^{[8
]}

Tan, H. ^{[7
]}

Berstein, G. ^{[9
]}

机构：

[1] Ghent Univ Hosp, Ghent, Belgium

[2] Fed Acad Teaching Hosp Feldkirch, Feldkirch, Austria

[3] Clin Dermacross, Santiago, Chile

[4] Univ Med Sch, Comprehens Ctr Inflammat Med, Schleswig Holstein Campus, Lubeck, Germany

[5] Univ Paris Diderot, Hop St Louis, APHP, Sorbonne Paris Cite, Paris, France

[6] Aarhus Univ Hosp, Aarhus C, Denmark

[7] Pfizer Inc, Groton, CT 06340 USA

[8] Pfizer Inc, New York, NY USA

[9] Pfizer Inc, Cambridge, MA USA

来源：

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2016年 / 30卷

关键词：

etanercept; psoriasis; tofacitinib;

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P152

引用

页码：78 / 78

页数：1

共 50 条

[1] Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
Bachelez, Herve
van de Kerkhof, Peter C. M.
Strohal, Robert
Kubanov, Alexey
Valenzuela, Fernando
Lee, Joo-Heung
Yakusevich, Vladimir
Chimenti, Sergio
Papacharalambous, Jocelyne
Proulx, James
Gupta, Pankaj
Tan, Huaming
Tawadrous, Margaret
Valdez, Hernan
Wolk, Robert
[J]. LANCET, 2015, 386 (9993): : 552 - 561
[2] Predictors of response to tofacitinib or etanercept in a phase 3 randomized, noninferiority study in patients with moderate to severe chronic plaque psoriasis
Lambert, Jo
Strohal, Robert
de la Cruz, Claudia
Thaci, Diamant
Bachelez, Herve
Iversen, Lars
Rottinghaus, Scott
Tallman, Anna
Tan, Huaming
Berstein, Gabriel
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB263 - AB263
[3] Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study
Valenzuela, F.
Paul, C.
Mallbris, L.
Tan, H.
Papacharalambous, J.
Valdez, H.
Mamolo, C.
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (10) : 1753 - 1759
[4] Tofacitinib exposure-response characteristics in patients with moderate to severe chronic plaque psoriasis
Gupta, Pankaj
Hutmacher, Matthew
Papp, Kim
Lebwohl, Mark
Ito, Kaori
Tan, Huaming
Wolk, Robert
Mebus, Charles
Rottinghausi, Scott T.
Valdez, Hernan
Mallbris, Lotus
Krishnaswami, Sriram
[J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S8 - S8
[5] EXPOSURE-RESPONSE CHARACTERISTICS AND PREDICTORS OF EFFICACY IN MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS PATIENTS RECEIVING TOFACITINIB.
Hutmacher, M. M.
Papp, K. A.
Lebwohl, M.
Ito, K.
Tan, H.
Wolk, R.
Mebus, C.
Rottinghaus, S.
Valdez, H.
Krishnaswami, S.
Gupta, P.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S52 - S52
[6] PREDICTORS OF RESPONSE TO TILDRAKIZUMAB FOR MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Blauvelt, Andrew
Reich, Kristian
Papp, Kim A.
Tyring, Stephen K.
Sinclair, Rodney
Thaci, Diamant
Gooderham, Melinda
Li, Qing
Cichanowitz, Nicole
La Rosa, Carmen
[J]. ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 22 - 22
[7] Pharmacokinetic Characteristics of Tofacitinib in Adult Patients With Moderate to Severe Chronic Plaque Psoriasis
Ma, Guangli
Xie, Rujia
Strober, Bruce
Langley, Richard
Ito, Kaori
Krishnaswami, Sriram
Wolk, Robert
Valdez, Hernan
Rottinghaus, Scott
Tallman, Anna
Gupta, Pankaj
[J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2018, 7 (06): : 587 - 596
[8] Predictors of response to tildrakizumab for moderate-to-severe chronic plaque psoriasis
Blauvelt, Andrew
Reich, Kristian
Papp, Kim A.
Tyring, Stephen K.
Sinclair, Rodney
Thaci, Diamant
Gooderham, Melinda
Li, Qing
Cichanowitz, Nicole
la Rosa, Carmen
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB226 - AB226
[9] Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: A phase 3 randomized trial
Bissonnette, R.
Iversen, L.
Sofen, H.
Griffiths, C. E. M.
Foley, P.
Romiti, R.
Bachinsky, M.
Rottinghaus, S. T.
Tan, H.
Proulx, J.
Valdez, H.
Gupta, P.
Mallbris, L.
Wolk, R.
[J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2015, 56 : 37 - 37
[10] Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials
Menter, M. Alan
Papp, Kim A.
Cather, Jennifer
Leonardi, Craig
Pariser, David M.
Krueger, James G.
Wohlrab, Johannes
Amaya-Guerra, Mario
Kaszuba, Andrzej
Nadashkevich, Oleg
Tsai, Tsen-Fang
Gupta, Pankaj
Tan, Huaming
Valdez, Hernan
Mallbris, Lotus
Tatulych, Svitlana
[J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2016, 15 (05) : 568 - 580

← 1 2 3 4 5 →